公众号 / 文章神经儿科影像MR

当前实践:遗传性出血性毛细血管扩张症儿童脑部血管畸形筛查的依据

Current Practice: Rationale for Screening Children with Hereditary Hemorrhagic Telangiectasia for Brain Vascular Malformations.
PubMed 文献 · AJNR Am J Neuroradiol · 2024-09-09

本文由遗传性出血性毛细血管扩张症多学科专家组撰写,综述支持对该病儿童在诊断时进行对比增强MR筛查脑部血管畸形的证据并反驳反对筛查的观点。儿童以高流量病变(含AVF)为主,破裂风险约每病变每年0.7%且随病变数量和终生累积,专家组不认可「观察等待」策略。

要点

  • 遗传性出血性毛细血管扩张症儿童脑部血管畸形以高流量病变为主,其中AVF破裂风险最高。
  • 国际指南推荐在该病诊断时用对比增强MR筛查儿童脑部血管畸形。
  • 儿童破裂风险约每病变每年0.7%,且随病变数量及终生累积。

核心结论

  • 专家组审阅支持筛查指南的证据并反驳反对筛查的论点,认为「观察等待」策略不可接受。
  • 儿童遗传性出血性毛细血管扩张症以高流量病变(含AVF)为主,破裂风险约每病变每年0.7%且随病变数量及终生累积。
  • ARUBA试验为成人未破裂散发性脑AVM的临床试验,5年结果支持保守药物治疗,但因儿童预期寿命长而不适用于儿童遗传性出血性毛细血管扩张症患者。
  • 介入、放射外科和外科技术随时间已有改进,有经验的神经血管专家可根据当地资源前瞻性确定每个儿童的最佳治疗。

研究设计与样本

  • 本文为多学科遗传性出血性毛细血管扩张症专家组对支持筛查指南证据及反对筛查论点的综述分析。
  • 国际遗传性出血性毛细血管扩张症诊断与管理指南推荐在该病诊断时用对比增强MR筛查儿童脑部血管畸形。
  • 反对筛查的论点包括将成人ARUBA试验的短期数据外推到儿童、对镇静或静脉对比剂使用的担忧以及增加患者或家庭焦虑。

关键影像表现/征象

  • 脑部血管畸形包括高流量AVM和AVF以及低流量毛细血管畸形。
  • 高流量病变可破裂,导致神经功能病残和死亡。
  • 儿童遗传性出血性毛细血管扩张症以高流量病变(含AVF)为主,后者破裂风险最高。

诊断标准与关键数值

  • 国际指南推荐在遗传性出血性毛细血管扩张症诊断时用对比增强MR筛查儿童脑部血管畸形。
  • 儿童破裂风险估计约每病变每年0.7%,且随病变数量及终生累积。
  • 脑部血管畸形在遗传性出血性毛细血管扩张症患者中约占10%。

临床应用与阅片要点

  • 国际指南推荐在该病诊断时用对比增强MR筛查儿童脑部血管畸形。
  • 反对筛查者认为筛查未获统一采用且依据不足,理由包括外推成人ARUBA短期数据、镇静或静脉对比剂担忧及增加焦虑。
  • 专家组认为「观察等待」策略不可接受,因病变直至发生危及生命和致残的脑出血才被发现。
  • 有经验的神经血管专家可根据当地资源前瞻性确定每个儿童的最佳治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Hereditary hemorrhagic telangiectasia is an autosomal dominant vascular dysplasia characterized by mucocutaneous telangiectasias, recurrent epistaxis, and organ vascular malformations including in the brain, which occur in about 10% of patients. These brain vascular malformations include high-flow AVMs and AVFs as well as low-flow capillary malformations. High-flow lesions can rupture, causing neurologic morbidity and mortality.

STATE OF PRACTICE: International guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia recommend screening children for brain vascular malformations with contrast enhanced MR imaging at hereditary hemorrhagic telangiectasia diagnosis. Screening has not been uniformly adopted by some practitioners who contend that screening is not justified. Arguments against screening include application of short-term data from the adult A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA) trial of unruptured sporadic brain AVMs to children with hereditary hemorrhagic telangiectasia as well as concerns about administration of sedation or IV contrast and causing patients or families increased anxiety.

ANALYSIS: In this article, a multidisciplinary group of experts on hereditary hemorrhagic telangiectasia reviewed data that support screening guidelines and counter arguments against screening. Children with hereditary hemorrhagic telangiectasia have a preponderance of high-flow lesions including AVFs, which have the highest rupture risk. The rupture risk among children is estimated at about 0.7% per lesion per year and is additive across lesions and during a lifetime. ARUBA, an adult clinical trial of expectant medical management versus treatment of unruptured brain AVMs, favored medical management at 5 years but is not applicable to pediatric patients with hereditary hemorrhagic telangiectasia given the life expectancy of a child. Additionally, interventional, radiosurgical, and surgical techniques have improved with time. Experienced neurovascular experts can prospectively determine the best treatment for each child on the basis of local resources. The "watch and wait" approach to imaging means that children with brain vascular malformations will not be identified until a potentially life-threatening and deficit-producing intracerebral hemorrhage occurs. This expert group does not deem this to be an acceptable trade-off.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Beslow LA, White AJ, Krings T, et al. Current Practice: Rationale for Screening Children with Hereditary Hemorrhagic Telangiectasia for Brain Vascular Malformations. AJNR Am J Neuroradiol. 2024. PMID: 38816017. doi:10.3174/ajnr.A8195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。